Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Halozyme ( (HALO) ).
On May 5, 2026, Halozyme Therapeutics, Inc. held its Annual Meeting of Stockholders, with 104,138,244 of 118,474,300 eligible shares represented, to vote on board elections, executive compensation and auditor ratification. Stockholders re-elected Class I directors Bernadette Connaughton and Matthew L. Posard to three-year terms and approved the advisory vote on executive pay, while also ratifying Ernst & Young LLP as the company’s independent auditor for the 2026 fiscal year, signaling continued shareholder support for current governance, compensation practices and financial oversight.
These voting outcomes reinforce the stability of Halozyme’s leadership and its existing strategic direction, as both director nominees received more than a majority of outstanding shares in favor. The strong backing for executive compensation and the reappointment of Ernst & Young LLP as auditor indicates investor confidence in management’s stewardship and the reliability of the company’s financial reporting, with no significant shareholder rebellion evident in the voting results.
The most recent analyst rating on (HALO) stock is a Buy with a $95.00 price target. To see the full list of analyst forecasts on Halozyme stock, see the HALO Stock Forecast page.
Spark’s Take on HALO Stock
According to Spark, TipRanks’ AI Analyst, HALO is a Outperform.
The score is driven primarily by strong financial performance (high-margin scale and standout free-cash-flow generation) and supportive earnings-call guidance for continued revenue/royalty growth. These strengths are partially offset by weak technical momentum (below key moving averages with negative MACD) and a valuation that is reasonable but not clearly discounted given no dividend yield support.
To see Spark’s full report on HALO stock, click here.
More about Halozyme
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing therapies that leverage its proprietary drug-delivery and biologics technologies. The company operates in the biopharmaceutical industry, partnering with other drugmakers to enhance the delivery and performance of injectable treatments in global markets.
Average Trading Volume: 1,601,757
Technical Sentiment Signal: Buy
Current Market Cap: $7.86B
For an in-depth examination of HALO stock, go to TipRanks’ Overview page.